V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 260016978 | 260009926 | 1.67 | 61.9 | Palliative (P) | 2017-11-02 | 2017-11-02 | Carboplatin 21day + Paclitaxel 7day | 02 | N | 260006047 | CARBOPLATIN + PACLITAXEL |
| 260016979 | 260019395 | 1.63 | 74.7 | Curative (C) | 2017-11-27 | 2017-12-04 | Pemetrexed | N | N | 260006875 | LIPOSOMAL DOXORUBICIN |
| 260016980 | 260009930 | 1.58 | null | Palliative (P) | 2018-02-25 | 2018-07-07 | TRASTUZUMAB | N | N | 260007052 | DOCETAXEL + TRASTUZUMAB |
| 260016981 | 260009935 | 1.77 | 75 | Curative (C) | 2015-12-05 | 2016-01-03 | IFOSFAMIDE + PACLITAXEL | 99 | N | 260007190 | GEMCARBO |
| 260016982 | 260009937 | 1.72 | 96 | Disease modification (D) | 2015-10-23 | 2015-11-06 | CARBO + THIOTEPA + TOPOTECAN | 02 | N | 260007261 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 260016983 | 260009944 | 1.69 | 62.3 | Adjuvant (A) | 2015-02-20 | 2015-02-21 | Cyclophosphamide PO +Vinorelbine IV | 02 | N | 260007582 | BLEOMYCIN + VINCRISTINE |
| 260016984 | 260014725 | 1.63 | 86.5 | Palliative (P) | 2017-08-11 | 2017-08-11 | Bendamustine + Obinutuzumab | N | N | 260007760 | VINCRISTINE |
| 260016985 | 260009947 | null | null | Curative (C) | 2017-06-18 | 2017-06-22 | CISPLATIN + VINORELBINE + RT | N | N | 260007834 | CETUXIMAB |
| 260016986 | 260009948 | 1.78 | 66 | Curative (C) | 2017-03-22 | 2017-03-25 | IVA | 2 | N | 260007834 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 260016987 | 260009951 | 1.8 | 50 | Disease modification (D) | 2018-03-20 | 2018-07-25 | BLEOMYCIN + CISPLATIN + VINCRISTINE | N | N | 260007862 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 260016988 | 260009955 | 1.74 | 55.3 | null | 2018-09-21 | 2018-10-09 | IFOSFAMIDE + PACLITAXEL | null | null | 260007889 | VIP |
| 260016989 | 260009958 | 1.67 | 87.8 | Disease modification (D) | 2015-08-19 | 2015-08-19 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + PACLITAXEL | 2 | N | 260007890 | CARBOPLATIN + THIOTEPA + TOPOTECAN |
| 260016990 | 260009964 | null | 78.9 | Palliative (P) | 2018-10-20 | 2019-04-04 | Gemcitabine + Paclitaxel | N | null | 260007966 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260016991 | 260009969 | 1.81 | 81 | Curative (C) | 2016-09-23 | 2016-09-30 | Vinblastine weekly | 02 | N | 260008037 | VINBLASTINE |
| 260016992 | 260009972 | 1.56 | 66.3 | Disease modification (D) | 2016-12-03 | 2017-06-26 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | 02 | Y | 260008231 | ICE |
| 260016993 | 260014728 | 1.81 | 80.6 | Disease modification (D) | 2017-01-19 | 2017-03-04 | BLEOMYCIN + VINCRISTINE | N | N | 260008282 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260016994 | 260009975 | 1.66 | null | Curative (C) | 2017-09-04 | 2017-10-23 | Vinblastine | Y | N | 260008307 | BLEOMYCIN + CISPLATIN + VINCRISTINE |
| 260016995 | 260014729 | 1.58 | null | Disease modification (D) | 2014-11-26 | 2015-01-21 | BLEOMYCIN + VINCRISTINE | N | N | 260008373 | CVP |
| 260016996 | 260009982 | 1.84 | 57.2 | Curative (C) | 2018-05-27 | 2018-05-27 | Cisplatin + Vinorelbine (IV) | 99 | N | 260008455 | CISPLATIN + VINORELBINE |
| 260016997 | 260014731 | 1.87 | 87.1 | Adjuvant (A) | 2015-10-04 | 2015-10-11 | BLEOMYCIN | N | N | 260008540 | RMS 2005 TRIAL |
| 260016998 | 260014731 | null | 72.3 | Curative (C) | 2016-06-05 | 2016-09-23 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE + PACLITAXEL | N | null | 260008540 | MAP |
| 260016999 | 260019370 | 1.7 | 72 | Disease modification (D) | 2015-06-06 | 2015-06-15 | ACE (germ cell) | 02 | N | 260008571 | EP |
| 260017000 | 260009987 | 1.66 | 93 | Palliative (P) | 2014-05-11 | 2014-05-11 | BLEOMYCIN | 2 | N | 260008643 | CHLORAMBUCIL + RITUXIMAB |
| 260017001 | 260009990 | 1.8 | 0 | Curative (C) | 2017-10-23 | 2017-10-27 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE | 2 | N | 260008705 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 260017002 | 260014735 | 1.54 | 93.7 | Disease modification (D) | 2018-12-30 | 2018-12-30 | CISPLATIN + GEMCITABINE + RITUXIMAB | 02 | N | 260008733 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 260017003 | 260009992 | null | null | Curative (C) | null | 2016-07-25 | Cetuximab 7 day (>Cycle 2) | null | N | 260008781 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 260017004 | 260014736 | 1.78 | 85 | Curative (C) | 2016-11-16 | 2017-05-31 | CARBOPLATIN + EPIRUBICIN + ETOPOSIDE + MELPHALAN | N | N | 260008789 | ICE |
| 260017005 | 260009995 | 1.78 | 77 | Disease modification (D) | 2014-11-10 | 2014-11-10 | ACE (germ cell) | 02 | N | 260008903 | BLEOMYCIN + VINCRISTINE |
| 260017006 | 260009996 | 1.68 | 57.1 | Palliative (P) | 2016-01-12 | 2016-01-13 | NIVOLUMAB | 02 | N | 260008930 | TRASTUZUMAB |
| 260017007 | 260009999 | null | 64.6 | Palliative (P) | 2017-01-03 | 2017-01-07 | POMB | N | N | 260008975 | IVADO |
| 260017008 | 260010003 | 1.76 | 65.4 | Disease modification (D) | 2018-08-31 | 2018-09-12 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 02 | N | 260009010 | VINORELBINE |
| 260017009 | 260014741 | 1.81 | 92.9 | Palliative (P) | 2018-09-06 | 2018-10-08 | CYCLOPHOSPHAMIDE + VINORELBINE | N | N | 260009037 | BLEOMYCIN + VINCRISTINE |
| 260017010 | 260010007 | null | 115.7 | Curative (C) | 2016-02-16 | 2016-02-20 | BLEOMYCIN + CISPLATIN + VINCRISTINE | 2 | N | 260009056 | CARBO + THIOTEPA + TOPOTECAN |
| 260017011 | 260014742 | 1.61 | 58.3 | Palliative (P) | 2017-01-06 | 2017-01-22 | DOCETAXEL + TRASTUZUMAB | N | N | 260009099 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 260017012 | 260010011 | 1.71 | 87.8 | Adjuvant (A) | 2015-12-12 | 2015-12-17 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE | 2 | null | 260009143 | BLEOMYCIN + CARBOPLATIN + CISPLATIN + VINCRISTINE |
| 260017013 | 260010013 | 1.74 | null | Curative (C) | 2016-12-29 | 2017-01-05 | Obinutuzumab | N | N | 260009188 | CISPLATIN + ETOPOSIDE + IFOSFAMIDE |
| 260017014 | 260014743 | 1.69 | 66.5 | Adjuvant (A) | 2015-06-16 | 2015-11-28 | VIP | N | null | 260009288 | IVADO |
| 260017015 | 260010015 | null | 61 | Disease modification (D) | 2015-06-30 | 2016-01-22 | TRASTUZUMAB | N | N | 260009334 | CARBOPLATIN + PACLITAXEL |
| 260017016 | 260010016 | 1.68 | null | Curative (C) | 2017-10-05 | 2019-02-22 | TRASTUZUMAB | N | N | 260009422 | CISPLATIN + GEMCITABINE + RITUXIMAB |
| 260017017 | 260010019 | 1.72 | null | Curative (C) | 2017-07-29 | 2017-08-08 | CYTARABINE + METHOTREXATE HD | N | N | 260009510 | GEMCITABINE + OXALIPLATIN |
| 260017018 | 260010023 | 1.5 | 56.4 | Curative (C) | 2017-01-12 | 2017-01-25 | TRASTUZUMAB | N | N | 260009538 | TRASTUZUMAB |
| 260017019 | 260010026 | null | 73 | Curative (C) | 2015-11-25 | 2015-12-04 | DOCETAXEL + TRASTUZUMAB | 2 | N | 260009710 | CYTARABINE HD + METHOTREXATE HD |
| 260017020 | 260010028 | 1.72 | null | Palliative (P) | 2018-05-23 | 2018-08-23 | OSIMERTINIB | N | N | 260009772 | CARBO + THIOTEPA + TOPOTECAN |
| 260017021 | 260014750 | 1.5 | 74 | Curative (C) | 2016-07-24 | 2016-07-24 | CARBOPLATIN + ETOPOSIDE + IFOSFAMIDE | N | N | 260009790 | CARBOPLATIN + PACLITAXEL |
| 260017022 | 260014751 | 1.62 | 72.6 | Palliative (P) | 2016-06-10 | 2016-06-10 | FEC 60 or 75 | N | N | 260009791 | TRASTUZUMAB |
| 260017023 | 260010032 | 1.82 | 89 | Disease modification (D) | 2017-03-24 | 2017-03-28 | CISPLATIN + EPIRUBICIN | N | N | 260009931 | EP |
| 260017024 | 260010035 | 1.67 | 80 | Disease modification (D) | 2017-08-25 | 2017-08-25 | Cytarabine HD + Methotrexate HD | 2 | N | 260010022 | FEC |
| 260017025 | 260010036 | 1.77 | 81 | Curative (C) | 2019-10-13 | 2019-10-13 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | Y | N | 260010054 | CARBOPLATIN + ETOPOSIDE |
| 260017026 | 260010039 | 1.7 | 77 | Palliative (P) | 2016-01-18 | 2016-03-14 | CARBOPLATIN + ETOPOSIDE | N | N | 260010054 | EP |
| 260017027 | 260010040 | 1.63 | 64.7 | Neo-adjuvant (N) | 2018-09-07 | 2018-09-08 | Vinblastine | 02 | null | 260010109 | EP |